AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02108184
Drug: Concomitant therapy 10 days
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (pantoprazole 40 mg + amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg ) bid for 10 days : Concomitant therapy 1
Trial: NCT02108184
Drug: Concomitant therapy 14 days
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (pantoprazole 40 mg +amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg bid) for 14 days : Concomitant therapy 2
Trial: NCT01026311
Drug: Coenzyme q 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of Coenzyme q 10
Trial: NCT01026311
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 placebo q d during treatment period
Trial: NCT00557089
Drug: rhDNAse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg rhDNase will be dispensed in 2.5 ml vials and administered once a day for 28 days. Treatment will be administered by inhalation.
Trial: NCT00400842
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04080544
Drug: [18F]AV-1451
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subject will receive up to a target dose of 370 megabecquerel (MBq) as a single IV bolus of \[18F\]AV-1451.
Trial: NCT00463697
Drug: GW642444H (100mcg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H salt
Trial: NCT00463697
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00463697
Drug: GW642444M (25, 100 & 400 mcg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M salt
Trial: NCT02867345
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant).
Trial: NCT00518219
Drug: TW
RxNorm normalized name: Etwon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TW,120mg/d
Trial: NCT01682499
Drug: calcium gluconate and magnesium sulfate
RxNorm normalized name: Calcium Gluconate
DrugBank: Calcium gluconate (DB11126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous calcium gluconate and magnesium sulfate, 1g each agent in 100 ml D5W over 30 minutes, immediately before and after each dose of paclitaxel
Trial: NCT00492856
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00492856
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT00492856
Drug: tretinoin
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00315705
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 340-440 mg/m²/day as 30-60 minute intravenous (IV) infusion daily for 5 days of a 28 day cycle following the other two interventions. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.
Trial: NCT00148005
Drug: Anticholinergic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02551198
Drug: SUCLEAR®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm2: SUCLEAR® (oral sulfate solution; OSS): OSS(1b/177mL)\[PM 7-9, the day before colonoscopy\] + OSS(1b/177mL)\[AM 5-7, the day of colonoscopy\]
Trial: NCT01919918
Drug: Muscle Contraction with Metabolite Solution Administration
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will perform maximal elbow flexor or knee extensor contractions before and after administration of metabolite solutions of pH 7.2, pH 7.0 and pH 6.6
Trial: NCT01346371
Drug: Refresh Tears 0.5% Lubricant Eye Drops
RxNorm normalized name: Refresh Tears 0.5% Lubricant Eye Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01346371
Drug: Bepreve 1.5% Ophthalmic Solution
RxNorm normalized name: Bepreve 1.5% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03508141
Drug: Cryoprecipitate
RxNorm normalized name: Cryoprecipitate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator
Trial: NCT02310802
Drug: OBE001 dose 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OBE001 dispersible tablets for single oral administration
Trial: NCT02310802
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo dispersible tablets for single oral administration
Trial: NCT00338312
Drug: Testosterone Transdermal System
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: testosterone patch (300 mcg/day) patch changed 2 times/week, for one year
Trial: NCT00338312
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo patch changed twice a week for one year
Trial: NCT00649779
Drug: VoSpire™ ER 8 mg tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8mg, single dose fasting
Trial: NCT03192527
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator.
Trial: NCT04641312
Drug: LY3457263
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT04641312
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT00783211
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, once daily for 15 days
Trial: NCT01870024
Drug: Fosphenytoin
RxNorm normalized name: Fosphenytoin
DrugBank: Fosphenytoin (DB01320)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: fosphenytoin 20 mg/kg Equivalent Phenytoin (EP) by intravenous infusion over a period of 15 minutes
Trial: NCT01870024
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 20 mg/kg by intravenous infusion over a period of 15 minutes
Trial: NCT01658501
Drug: 50 mg PB1023
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01658501
Drug: 70 mg PB1023
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01658501
Drug: 100 mg PB1023
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01658501
Drug: Placebo (0.9% Sodium Chloride)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01658501
Drug: Victoza®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01658501
Drug: Sulfonylurea
RxNorm normalized name: Sulfonylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01658501
Drug: Metformin and Sulfonylurea
RxNorm normalized name: metformin and sulfonylureas
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01386255
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo. No other names
Trial: NCT04371107
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: azithromycin treatment 500 mg on day 1 then 250 mg the following 4 days from day 2 to day 5, per os.
Trial: NCT00620685
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, once daily for 4 weeks
Trial: NCT02918812
Drug: Intramuscular Diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular Diclofenac 30 mins before HSG
Trial: NCT01650584
Drug: ISTA Tears
RxNorm normalized name: PEG-400/Propylene Glycol 0.4%-0.3% Ophthalmic Solution [VISTA TEARS DRY EYE RELIEF]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sterile ophthalmic solution
Trial: NCT00001261
Drug: Gamma Globulin
RxNorm normalized name: Gamma globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03846583
Drug: Aromatase Inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: These drugs act by lowering the amount of estrogen produced by the body by blocking an enzyme called aromatase
Trial: NCT00354692
Drug: Sodium Ferric Gluconate and Iron sucrose
RxNorm normalized name: FERRIC NA GLUCONATE
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03544944
Drug: TJP-008-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects who are randomized into group TJP-008-1 will receive bowel preparation on the same-day.
Trial: NCT03544944
Drug: TJP-008-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects who are randomized into group TJP-008-2 will receive bowel preparation from evening to next morning.
Trial: NCT03544944
Drug: Coolprep powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects who are randomized into group Coolprep will receive bowel preparation from evening to next morning.
Trial: NCT03016975
Drug: Guideline Directed Medical Therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDMT Only
Trial: NCT01590797
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo once daily for 24 weeks
Trial: NCT00380744
Drug: LY2189102
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00380744
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03179423
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly IV repeated dose
Trial: NCT01338870
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets (n=4), 0 mg twice daily for 84 days
Trial: NCT04368351
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dose: 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day)
Trial: NCT02943590
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A pill taken once a day
Trial: NCT02369302
Drug: DWC20142
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT02369302
Drug: DWC20141, DWC20142
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT01233739
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of 2 capsules of placebo orally.
Trial: NCT00002638
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04218734
Drug: DBPR108
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBPR108: 100 mg, once daily for 24 weeks.
Trial: NCT04218734
Drug: placepo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo:100 mg, once daily for 24 weeks.
Trial: NCT03731442
Drug: PEG-rhG-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-rhG-CSF 3-6mg, 48 hours after chemotherapy
Trial: NCT02520518
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01346787
Drug: CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will start induction treatment with Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15. Low dose Dexamethasone will be given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days 1-2, 8-9,15-16, 22-23. Carfilzomib = 20 mg/m2 IV once daily on days 1, 2, of cycle 1 only followed by 36 mg/ m2 days 8, 9, 15, 16 in cycle 1, then for all subsequent doses 36 mg/ m2 IV once daily on days 1, 2, 8, 9, 15, 16, followed by 13-day rest period (day 17 through 28). Each cycle will be repeated every 28 days for a total of 9 courses. MANTEINANCE PERIOD At the end of induction phase (9 courses), maintenance phase with Carfilzomib alone IV at 36 mg/ m2 IV on days 1, 2, 15, 16 will start, until progression or intolerance. For patients who show evidence of progression during maintenance phase, the frequency of Carfilzomib can be increased to days 1, 2, 8, 9, 15, 16 at the discretion of the investigator, or the patient may be removed from the study
Trial: NCT02655705
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Initial dose with 10 mg/week, increasing 2.5 mg every 2 weeks up to 15 mg/week maintenance dose
Trial: NCT00100308
Drug: Unfractioned heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose continuous-infusion, 500 units/hour per seven days
Trial: NCT00447876
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride: 2 ml injected at the root of the plantar fascia
Trial: NCT04355065
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: These patients continue their stable pharmacological treatment and do not receive any additional cognitive intervention.~They are contacted weekly by phone to follow up on the group.
Trial: NCT02432157
Drug: Standard fluid management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine fluid management strategy as pre-specified by our SAH management protocol.
Trial: NCT00717379
Drug: Methylprednisolone or equivalent
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01653717
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 250 mg/kg by vein on Days -5 to -3.
Trial: NCT01121081
Drug: Alga Dunaliella Bardawil
RxNorm normalized name: Dunaliella salina extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 capsules per day, 2 in the morning 2 in the evening for 3 month
Trial: NCT01121081
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Alga Dunaliella Bardawil~4 capsules per day, 2 in the morning 2 in the evening for 3 month
Trial: NCT02422797
Drug: DTG 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received one oral tablet of 50 mg DTG daily administered concomitantly with RPV. Each DTG tablet contained 52.62 mg dolutegravir sodium salt, which was equivalent to 50 mg dolutegravir free acid.
Trial: NCT02422797
Drug: RPV 25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received DTG 50 milligrams (mg) + RPV 25 mg together once daily at approximately the same time, with a meal, in an open-label fashion up to Week 52 during early switch phase. Participants continued to receive DTG 50 mg + RPV 25 mg up to Week 148 during the Late Switch Phase.~Participants who successfully completed 148 weeks of treatment were given the opportunity to continue to receive DTG + RPV once daily in the Continuation Phase (after Week 148), one oral tablet of 25 mg RPV daily administered concomitantly with DTG along with a meal. Each RPV tablet contained 27.5 mg of rilpivirine hydrochloride, which was equivalent to 25 mg of RPV.
Trial: NCT01038297
Drug: EXC 001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injections of EXC 001 and placebo given on various schedules.
Trial: NCT00446485
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo during 6 months
Trial: NCT01038297
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injections of EXC 001 and placebo given on various schedules.
Trial: NCT00766779
Drug: Non-Transplant treatment approach for consolidation
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive the treatment that would be otherwise applied at the local institution. The consolidation or maintenance therapy is according to the study group protocol.
Trial: NCT00003577
Drug: CMF regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003577
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003577
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003577
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04648423
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution for oral administration
Trial: NCT01528007
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill with no active ingredients.
Trial: NCT04010786
Drug: NNC0247-0829
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive either single or multiple doses given subcutaneously (s.c., under the skin) in a lifted fold of the stomach skin. Dose level and number of doses will depend on the cohort.
Trial: NCT04010786
Drug: Placebo (NNC0247-0829)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive either single or multiple doses of placebo given s.c. in a lifted fold of the stomach skin.
Trial: NCT03055403
Drug: M201-A Injection
RxNorm normalized name: OCTINOXATE 2.45 g in 35 g / TITANIUM DIOXIDE 4.03 g in 35 g / ZINC OXIDE 1.72 g in 35 g / OCTISALATE 1.58 g in 35 g TOPICAL CREAM [15HR COVER LASTING M201 Medium Beige SPF50]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Substance: M201-A Route of administration: continuous intravenous injection
Trial: NCT03133650
Drug: WST 11-mediated VTP therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of WST11 in conjunction with endoscopic illumination at 753 nm emitted by a diode laser and administered to the participant by optical fibre catheters (cylindrical light diffusers) and a standard upper GI endoscope.
Trial: NCT00606164
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single one-hour intravenous infusion of placebo on Day 1
Trial: NCT00535405
Drug: Ezetimibe 10 mg/simvastatin 20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg/simvastatin 20 mg and Placebo for atorvastatin once daily for 12 weeks
Trial: NCT01496430
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02509598
Drug: Vital Blue Dye (optional)
RxNorm normalized name: Vital-Chlor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose 1-3 mL of vital blue dye (1%) administered intradermally at the start of or during surgery (optional, per institution's standard of care).
Trial: NCT00932152
Drug: Best supportive care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will not receive any chemotherapy for NSCLC nor will they received anti-cancer surgery, immunotherapy, radiotherapy or hormonal therapy. Among the therapies they may take are therapies considered acceptable include, but are not limited to, antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support (enteral or parenteral
Trial: NCT00188877
Drug: cisplatinium and fluorouracil - standard treatment
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00421343
Drug: calcium carbonate with cholecalciferol
RxNorm normalized name: calcium carbonate / cholecalciferol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: calcium carbonate 500mg /cholecalciferol 200IU orally twice daily
Trial: NCT03423186
Drug: SOBI003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly i.v.infusion
Trial: NCT00564330
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo bid
Trial: NCT03277924
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
Trial: NCT03277924
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
Trial: NCT02495623
Drug: SYN-010 21 mg
RxNorm normalized name: Gel-Syn
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02495623
Drug: SYN-010 42 mg
RxNorm normalized name: Gel-Syn
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02495623
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02889523
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m²/dose, D1
Trial: NCT02889523
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m²/dose, D1
Trial: NCT02889523
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg/m2 in the morning D1 to D5
Trial: NCT00360243
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02191241
Drug: Red Vine Leaf Extract
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01055808
Drug: Insulins
RxNorm normalized name: INSULINS AND ANALOGUES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual dose and frequency and duration as determined by the treating physician
Trial: NCT00657852
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml of 5% glucoside serum infusions within days 7-12 and at 3 months after liver transplantation and administered as a 4-hour continuous intravenous infusion